Bajaj Healthcare Limited has announced the reappointment of Sajankumar Bajaj as Chairman and Managing Director, ensuring leadership continuity at the pharmaceutical company.

Leadership Reappointment

The company's board has decided to continue with Sajankumar Bajaj's leadership by reappointing him to the dual role of Chairman and Managing Director. This decision reflects the board's confidence in his strategic vision and management capabilities.

Company Overview

Bajaj Healthcare Limited operates in the pharmaceuticals sector and is classified as a small-cap company. The reappointment of its key leadership position indicates stability in the company's management structure.

Strategic Continuity

The reappointment ensures that the company maintains its strategic direction under experienced leadership. Sajankumar Bajaj's continued role as Chairman and Managing Director provides operational consistency for the pharmaceutical company's ongoing business activities.

Bajaj Healthcare Limited delivered strong financial performance in Q3FY26, with the pharmaceutical company reporting significant growth across key metrics for the quarter ended December 31, 2025.

Strong Revenue Growth Drives Q3FY26 Performance

The company's revenue from operations surged 31.3% year-on-year to ₹16,122.27 crores in Q3FY26, compared to ₹12,279.40 crores in the corresponding quarter of the previous year. This represents a sequential growth of 9.0% from Q2FY26's revenue of ₹14,791.49 crores.

Nine-Month Performance Shows Consistent Growth

For the nine-month period ended December 31, 2025, Bajaj Healthcare maintained its growth trajectory with revenue from operations reaching ₹45,797.39 crores, representing an 18.0% increase from ₹38,812.99 crores in the corresponding period of FY25. Net profit for the nine-month period stood at ₹3,861.67 crores, up 36.4% from ₹2,831.77 crores in the previous year.

Operational Efficiency and Cost Management

The company's total expenses for Q3FY26 increased to ₹14,362.52 crores from ₹11,351.30 crores in Q3FY25. Key expense components included cost of materials consumed at ₹6,940.90 crores and other expenses at ₹3,425.87 crores. Despite higher expenses, the company maintained healthy profit margins with profit before tax reaching ₹1,924.46 crores, up 65.1% year-on-year.

Board Approves Key Leadership Reappointments

The Board of Directors approved several important reappointments during their meeting held on January 16, 2026:

The reappointments reflect the board's confidence in the existing leadership team's ability to drive continued growth and operational excellence.

Discontinued Operations and Strategic Focus

The company reported a loss of ₹42.71 crores from discontinued operations in Q3FY26, compared to a loss of ₹324.44 crores in Q3FY25. These discontinued operations relate to certain manufacturing units and land parcels that the company has classified as held for sale under its strategic restructuring initiatives.

Strong Earnings Per Share Performance

Basic earnings per share from total operations improved significantly to ₹4.96 in Q3FY26 from ₹3.65 in Q3FY25, representing a 35.9% increase. For continuing operations alone, basic EPS stood at ₹5.10 compared to ₹4.66 in the previous year quarter.